Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma

Jinyang Liu ¹, Miao He ²

⁰Department of Hepatobiliary and Pancreatic Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, China.

International Immunopharmacology +

|

May 18, 2024

View abstract on PubMed

Summary

This study developed an immune-related prognostic model for pancreatic ductal adenocarcinoma (PDAC). The model predicts patient outcomes and aids in assessing immunotherapy effectiveness for this aggressive cancer.

Area Of Science

Oncology
Immunology
Genomics

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited therapeutic strategies.
Understanding the role of immune cell infiltration in PDAC is crucial for improving patient outcomes.

Purpose Of The Study

To investigate the impact of immune cell infiltration on PDAC progression.
To develop and validate an immune-related prognostic model (IPM) for PDAC patients.

Main Methods

Utilized the International Cancer Genome Consortium (ICGC) cohort for model construction.
Employed Least Absolute Shrinkage and Selection Operator (LASSO) Cox analysis to identify key genes.
Validated the model using The Cancer Genome Atlas (TCGA) cohort and individual tumor samples.

Main Results

High immune infiltration correlated with a better prognosis in PDAC.
The developed IPM, based on four genes, identified a high-risk group with worse prognosis.
The IPM was confirmed as an independent risk factor for PDAC, with consistent validation results.

Conclusions

A novel immune-related prognostic prediction model for PDAC was successfully developed.
The IPM shows potential for enhancing immunotherapy measurement and prognostic assessment in PDAC patients.
A nomogram incorporating age and IPM demonstrated prognostic efficacy.

Keywords:

Immune infiltration Nomogram Pancreatic ductal adenocarcinoma Prognostic model Tumor microenvironment